Ian N. Fleming
Cyclacel Ltd.
Dundee
United Kingdom
Name/email consistency: high
- Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents. Fleming, I.N., Hogben, M., Frame, S., McClue, S.J., Green, S.R. Clin. Cancer Res. (2008)